tbuckley/cabot-search huggingface dataset:
Abstract 20168: Right Ventricular Stroke Work Correlates With Outcomes in Pediatric Pulmonary Arterial Hypertension (PAH) Patients
Authors: Weiguang Yang, Alison L Marsden, Michelle T Ogawa, Keely K Phillips, Marlene Rabinovitch, Jeffrey A Feinstein
Journal: Circulation (2016)

Introduction: Pulmonary arterial hypertension (PAH) is characterized by elevated pulmonary artery pressures and pulmonary vascular resistance. As no definitive treatment options exist, and lung transplant also carries significant mortality rates, optimizing treatment strategies and timing for transplant remains crucial; a quantitative measure to predict disease progression would be greatly beneficial in treatment planning. Hypothesis: We hypothesize that right ventricular (RV) stroke work correlates with clinical worsening in PAH patients. Methods: Pediatric patients (<18 years) with idiopathic PAH or PAH secondary to congenital heart diseases with serial, matched catheterization and magnetic resonance imaging (MRI) data were included. RV and PA hemodynamics were numerically simulated by a lumped parameter (circuit analogy) model to create patient-specific pressure-volume (PV) loops not easily replicated clinically. The model was tuned using optimization techniques to match patient-specific MRI and cath-d...
Genome-wide analyses reveal the IRE1a-XBP1 pathway promotes T helper cell differentiation by resolving secretory stress and accelerating proliferation
Authors: Jhuma Pramanik, Xi Chen, Gozde Kar, Johan Henriksson, Tomás Gomes, Jong-Eun Park, Kedar Natarajan, Kerstin B. Meyer, Zhichao Miao, Andrew N. J. McKenzie, Bidesh Mahata, Sarah A. Teichmann
Journal: Genome Medicine (2018)

The IRE1a-XBP1 pathway is a conserved adaptive mediator of the unfolded protein response. The pathway is indispensable for the development of secretory cells by facilitating protein folding and enhancing secretory capacity. In the immune system, it is known to function in dendritic cells, plasma cells, and eosinophil development and differentiation, while its role in T helper cell is unexplored. Here, we investigated the role of the IRE1a-XBP1 pathway in regulating activation and differentiation of type-2 T helper cell (Th2), a major T helper cell type involved in allergy, asthma, helminth infection, pregnancy, and tumor immunosuppression.We perturbed the IRE1a-XBP1 pathway and interrogated its role in Th2 cell differentiation. We performed genome-wide transcriptomic analysis of differential gene expression to reveal IRE1a-XBP1 pathway-regulated genes and predict their biological role. To identify direct target genes of XBP1 and define XBP1's regulatory network, we performed XBP1 ChIPmentation (ChIP-seq). We validated our predictions by flow cytometry, ELISA, and qPCR. We also used a fluorescent ubiquitin cell cycle indicator mouse to demonstrate the role of XBP1 in the cell cycle.We show that Th2 lymphocytes induce the IRE1a-XBP1 pathway during in vitro and in vivo activation. Genome-wide transcriptomic analysis of differential gene expression by perturbing the IRE1a-XBP1 pathway reveals XBP1-controlled genes and biological pathways. Performing XBP1 ChIPmentation (ChIP-seq) and integrating with transcriptomic data, we identify XBP1-controlled direct target genes and its transcriptional regulatory network. We observed that the IRE1a-XBP1 pathway controls cytokine secretion and the expression of two Th2 signature cytokines, IL13 and IL5. We also discovered that the IRE1a-XBP1 pathway facilitates activation-dependent Th2 cell proliferation by facilitating cell cycle progression through S and G2/M phase.We confirm and detail the critical role of the IRE1a-XBP1 pathway during Th2 lymphocyte activation in regulating cytokine expression, secretion, and cell proliferation. Our high-quality genome-wide XBP1 ChIP and gene expression data provide a rich resource for investigating XBP1-regulated genes. We provide a browsable online database available at http://data.teichlab.org .
PD-L1 expression pattern in large cell neuroendocrine carcinoma of the lung
Authors: D. Damotte, M.C. Charpentier, M. Bernardi, E. Watkin, I. Goubin Versini, R. Lamy, N. Piton, L. Geriniere, F. Forest, R. Gervais, I. Monnet, A. Madrosyk, F. Guisier, C. Serrand, C. Locher Genty, C. Decroisette, J.B. Auliac, T. Jeanfaivre, H. Doubre, D. Arpin
Journal: Annals of Oncology (2018)
Recurrent Pneumonitis Induced by Atezolizumab (Anti–Programmed Death Ligand 1) in NSCLC Patients Who Previously Experienced Anti-Programmed Death 1 Immunotherapy-Related Pneumonitis
Authors: Ping-Chih Hsu, Shih-Hong Li, Cheng-Ta Yang
Journal: Journal of Thoracic Oncology (2018)
P2.16-38 Characteristics of Preoperative N Staging in Patients with Optimal Pathologic N Staging of Non Small Cell Lung Cancer(NSCLC)
Authors: M. Ray, M. Smeltzer, N. Faris, Y. Lee, C. Fehnel, C. Houston-Harris, O. Akinbobola, P. Ojeabulu, E. Owen, R. Eubanks, H. Dox, D. Talton, G. Valaulikar, H. Wiggins, B. Wolf, P. Levy, E. Robbins, R. Osarogiagbon
Journal: Journal of Thoracic Oncology (2018)
Polymedication in elderly cancer patients treated with chemotherapy
Authors: A.-L. Couderc, F. Correard, C. Tabele, E. Nouguerede, L. Greillier, F. Duffaud, P. Auquier, A. Daumas, P. Bertault-Peres, P. Villani, S. Honore
Journal: Annals of Oncology (2018)
Combination of baseline LDH, performance status and age to identify solid tumor patients with higher probability of response to anti-PD1 and PDL1 monoclonal antibodies
Authors: M.S. Cona, M. Lecchi, S. Damian, M. Del Vecchio, C. Cimminiello, S. Cresta, M. Duca, A. Necchi, D. Signorelli, M. Poggi, D. Raggi, R. Ratta, P. Verderio, F.G.M. de Braud, M. Di Nicola
Journal: Annals of Oncology (2018)
Topline results from phase II of combination treatment with canerpaturev (HF10), an oncolytic viral immunotherapy, and ipilimumab in patients with unresectable or metastatic melanoma after anti-PD-1 therapy
Authors: T. Isei, K. Yokota, H. Uhara, Y. Fujisawa, T. Takenouchi, Y. Kiyohara, H. Uchi, H. Saruta, H. Ihn, T. Inozume, D. Watanabe, A. Takahashi, S. Fukushima, M. Tanaka, N. Yamazaki
Journal: Annals of Oncology (2018)
MA02.05 A Double-Blind, Randomized, Placebo-Controlled Phase 3 Noninferiority Study of Darbepoetin Alfa for Anemia in Advanced NSCLC
Authors: R. Nagarkar, P. Gascón, M. Šmakal, K. Syrigos, C. Barrios, J. Cárdenas Sánchez, L. Zhang, D. Tomita, J. Park, C. De Oliveira Brandao
Journal: Journal of Thoracic Oncology (2018)
Dramatic response of refractory sarcoidosis under ruxolitinib in a patient with associated JAK2-mutated polycythemia
Authors: Cécile Rotenberg, Valérie Besnard, Pierre-Yves Brillet, Stéphane Giraudier, Hilario Nunes, Dominique Valeyre
Journal: European Respiratory Journal (2018)

Sarcoidosis is a systemic disorder of unknown aetiology characterised by the formation of non-caseating epithelioid granulomas in involved organs. Although a spontaneous remission is frequent, up to 28–53% of patients may follow a persistent active course for more than 5 years [1, 2]. Outcome may be severe in a subset of these patients. Sarcoidosis treatment relies on three lines of therapies respectively corticosteroids, immunosuppressive medications and anti-tumour necrosis factor-α (anti-TNF-α) therapy according to severity. Potential role of the JAK-STAT pathway in sarcoidosis <http://ow.ly/L8Du30m78XI> The authors would like to thank J.F. Bernaudin (Dept of Respiratory Diseases, APHP, Avicenne Hospital, Bobigny, France) for his critical review and corrections of the manuscript.
Pharmacodynamic (PD) changes in tumors and peripheral blood T cell receptor (TCR) repertoire in a phase I study combining OX40 (PF-04518600) and 4-1BB (utomilumab) agonistic monoclonal antibodies (mAbs)
Authors: O. Hamid, S. Hu-Lieskovan, W. Ros, A. Diab, A.B. El-Khoueiry, J.A. Thompson, F.A. Eskens, J.-P. Spano, E. Angevin, N.A. Rizvi, J.S. Wasser, P.A. Ott, A. Chiappori, T. Joh, H.I. Krupka, S. Potluri, X. Wang, B.J. Ganguli, J. Chou, T. Doi
Journal: Annals of Oncology (2018)
Abstract 21364: Multicenter Prospective Study Comparing Phased Multipolar versus Traditional Radiofrequency Ablation
Authors: Zahra Azizi, Atul Verma, Pouria Alipour, Yaariv Khaykin, Peter Leong-Sit, Jean-Francois Sarrazin, Marcio Sturmer, Sherri Patterson, Carlos Morillo, Guy Amit, Jean-Francois Roux, Vidal Essebag
Journal: Circulation (2017)

Background: Multipolar, phased radiofrequency (RF) catheter ablation (PVAC) has been associated with reduced procedural times compared to traditional RF. We performed a multicenter study to assess the efficacy and efficiency of using this catheter. Methods: This is a multicenter, sequential, prospective, cohort study between 2012 to 2016 in 6 tertiary care centers (NCT01562912). Patients were enrolled if they had symptomatic, paroxysmal AF (less than 7 days) refractory to at least one antiarrhythmic medication. Patients were enrolled in a 2:1 ratio of PVAC (group A) to control point-by-point RF with 3D mapping (group B). ECG and 48 hour Holter monitor were used to assess patients at 3, 6, 9 and 12 months post-ablation follow up. Recurrence was defined as any atrial arrhythmia &gt;30 seconds excluding an initial 3 month blanking period. Results: Overall, 230 patients consisting of 162 males (70.4%) with mean age 57±11 years were analyzed. By Kaplan-Meier analysis, freedom from any atrial arrhythmia at 12 months was 49% and 69.2% in group A and B respectively (p=0.033) (Figure1). Among patients with recurrence, 14.7% (21) in group A and 7.7% (6) in group B had redo procedure within 12 month post procedure(p=0.12). Procedure time was significantly lower in Group A than Group B (P&lt;0.0001). There was no significant difference in fluoroscopy time between the two groups (p=0.49). Stroke was not reported in any of the patients. Pulmonary Embolism, occurred in 1.3% of patients in group B. Pericardial effusion occurred in 1.4% in group A and 2.6% in group B. Tamponade occurred in 3.8% of patients in group B. Conclusion: This study demonstrated that the PVAC catheter is associated with significantly reduced procedure times for AF ablation, however, AF recurrence rates may be higher than contemporary point-by-point RF ablation with 3D mapping technology.
Long-term results of postoperative chemoradiation therapy with capecitabine and oxaliplatin versus capecitabine alone for locally advanced rectal cancer: A randomized, multicenter, phase III trial
Authors: N. Li, J. Jin, Y. Li, Y. Zhu, W. Wang, J. Wang, Y. Feng, L. Liu, S. Wang, Y. Song, Y. Liu, Y. Tang, W. Liu, H. Ren, H. Fang
Journal: Annals of Oncology (2018)
Sidedness of the primary tumor on the effect of TAS-102 for refractory metastatic colorectal cancer
Authors: S. Ueda, Y. Tsuboguchi, Y. Nakatani, A. Tsuya, S.-I. Nishina, K. Akiyoshi, S. Okazaki, S. Tokunaga, H. Daga
Journal: Annals of Oncology (2018)
Association of grade ≥3 neutropenia (NP) with outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel
Authors: A. Meisel, R. de Wit, S. Oudard, O. Sartor, F. Stenner-Liewen, Z. Shun, A. Ozatilgan, M. Eisenberger, J.S. de Bono
Journal: Annals of Oncology (2018)
Microethics of Communication—Hidden Roles of Bias and Heuristics in the Words We Choose
Authors: Bryan A. Sisk, Justin N. Baker
Journal: JAMA Pediatrics (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Health-related quality of life (HRQoL) for pembrolizumab or placebo plus carboplatin and paclitaxel or nab-paclitaxel in patients with metastatic squamous NSCLC: Data from KEYNOTE-407
Authors: J. Mazières, D. Kowalski, A. Luft, D. Vicente, A. Tafreshi, M. Gümüş, K. Laktionov, B. Hermes, I. Cicin, J. Rodríguez-Cid, J. Wilson, T. Kato, R. Ramlau, S. Novello, S. Reddy, B. Piperdi, X. Li, T. Burke, L. Paz-Ares
Journal: Annals of Oncology (2018)
OA12.01 Phase II Data for the MET Inhibitor Tepotinib in Patients with Advanced NSCLC and MET Exon 14-Skipping Mutations
Authors: E. Felip, H. Sakai, J. Patel, L. Horn, R. Veillon, F. Griesinger, R. Bruns, J. Scheele, P. Paik
Journal: Journal of Thoracic Oncology (2018)
A positive correlation between the EZH2 and PD-L1 expression in patients with resected lung adenocarcinoma
Authors: G. Toyokawa, K. Takada, R. Hamamoto, Y. Yamada, T. Tagawa, F. Shoji, K. Yamazaki, Y. Oda, S. Takeo
Journal: Annals of Oncology (2018)
OA09.05 Potential Reduction in Lung Cancer Mortality in the US from 2015-2065: A Comparative Modeling Approach
Authors: J. Jeon, T. Holford, D. Levy, E. Feuer, P. Cao, J. Tam, L. Clarke, J. Clarke, C.Y. Kong, R. Meza
Journal: Journal of Thoracic Oncology (2018)
Abstract 17881: Overcoming the Tyranny of Distance- an Analysis of Out-Reach Visits to Optimise Secondary Prevention of Cardiovascular Disease in High Risk Individuals Living in Central Australia
Authors: Camilla Tuttle, Melinda Carrington, Simon Stewart, Alex Brown
Journal: Circulation (2014)

Introduction: Compared to the non-Indigenous of the population, Aboriginal Australians have a life expectancy that is 15-20 years less. Inequitable access to healthcare services (particularly in remote areas) contributes to this phenomenon. Objectives: We examined the logistical challenges of providing outreach visits, as part of an outreach, secondary prevention program in Central Australia for CVD. Methods: Prospective data from the Central Australia Heart Protection Study (n=200), a pragmatic, single-center, randomized study of a nurse-led, family-based, secondary prevention program designed to reduce major cardiac events, were analyzed. Clinical and logistic data were used to examine the characteristics of outreach visits for 50 consecutive subjects initially randomized to the study intervention. Results: Most subjects had presented with an acute coronary syndrome (44/50 [88%]) and 31 (62%) self-identified as Indigenous. Despite a similar gender profile (55% versus 58% Indigenous and non-Indigenous women), Indigenous subjects had a greater risk factor and co-morbid profile, with significantly more diabetes (77% vs. 26% p = 0.0002), hypertension (81% vs. 53% p = 0.04) and renal failure (52% vs. 21% p = 0.03). The community of origin of Indigenous subjects was 230 ± 208 km from the central hospital compared to 61 ± 150 km for the rest (p = 0.004). There was no difference in the number of subjects who missed initial baseline and ad hoc visits attended by the health care team according to ethnicity. However, perhaps reflecting their greater mobility, Indigenous subjects missed a significantly higher number of scheduled visits at 6 months (1.39 ± 2.14 vs. 0.16 ± 0.50 visits; p = 0.02). Finally, multivariate analyses (including all baseline profiling data) suggested that distance from Alice Springs did not influence completion of outreach visits. Conclusions: These data are invaluable to understanding and improving the cost dynamics and impact of secondary prevention for Indigenous adults living with heart disease remote from specialist health services.
P2.01-07 Safety and Efficacy of LATTICE Radiotherapy in Voluminous Non-Small Cell Lung Cancer: A Retrospective Study of 10 Patients Over 7 Year Period
Authors: B. Amendola, N. Perez, I. Qureshi, J. Melotek, M. Amendola, X. Wu
Journal: Journal of Thoracic Oncology (2018)
P1.11-03 MicroRNA with Ability to Reciprocal Regulation of Dicer and Drosha – Plasma Expression Status and Diagnostic Value in Non-Small Cell Lung Cancer
Authors: A. Grenda, M. Szczyrek, B. Kuźnar-Kamińska, P. Krawczyk, M. Sawicki, M. Głogowski, A. Rolska-Kopińska, G. Balicka, M. Nicoś, M. Jakimiec, H. Batura-Gabryel, D. Kowalski, R. Mlak, M. Krzakowski, J. Milanowski
Journal: Journal of Thoracic Oncology (2018)
Wendy Atkin: epidemiologist who made an enormous contribution to bowel cancer prevention
Authors: Penny Warren
Journal: BMJ (2018)

Julian Nieman

In October 2010, despite an atmosphere of cuts and austerity, Prime Minister David Cameron pledged £60m to incorporate flexible sigmoidoscopy into the NHS bowel screening programme. This followed the results of the UK Flexible Sigmoidoscopy Screening (UKFSS) trial,1 published in the Lancet and described by Harpal Kumar, chief executive of Cancer Research UK, as “a breakthrough. It is extremely rare to see the results of a clinical trial which are quite as compelling as this.”

The large randomised controlled trial found that a single screening reduced colorectal cancer incidence by a third and cut mortality by 43%. It was estimated that, once screening was rolled out, it could prevent 3000 deaths and 5000 new cases every year.

Patients spared the disease should thank Wendy Atkin—a remarkable epidemiologist who established and guided the trial for decades.

Wendy Atkin (nee Green) was born on 5 April 1947 and brought up in south London with her younger sister, Heather. Her father, David, was a pharmacist, and …
P1.01-38 A Phase II With a Lead-In Phase I Study to Examine Safety and Efficacy of Hydroxychloroquine and Gefitinib in Advanced NSCLC
Authors: Y. Huang, A. Wong, R. Soo, T. Soh, A. Pang, C.S. Tan, W. Ling, P.J. Voon, J. Lim, R. Sundar, N. Kumarakulasinghe, H.L. Lim, B.C. Goh, T.M. Chin
Journal: Journal of Thoracic Oncology (2018)
Genetic risk, incident stroke, and the benefits of adhering to a healthy lifestyle: cohort study of 306 473 UK Biobank participants
Authors: Loes CA Rutten-Jacobs, Susanna C Larsson, Rainer Malik, Kristiina Rannikmäe, Cathie L Sudlow, Martin Dichgans, Hugh S Markus, Matthew Traylor
Journal: BMJ (2018)

Abstract Objective To evaluate the associations of a polygenic risk score and healthy lifestyle with incident stroke. Design Prospective population based cohort study. Setting UK Biobank Study, UK. Participants 306 473 men and women, aged 40-73 years, recruited between 2006 and 2010. Main outcome measure Hazard ratios for a first stroke, estimated using Cox regression. A polygenic risk score of 90 single nucleotide polymorphisms previously associated with stroke was constructed at P&lt;1×10 −5 to test for an association with incident stroke. Adherence to a healthy lifestyle was determined on the basis of four factors: non-smoker, healthy diet, body mass index &lt;30 kg/m 2 , and regular physical exercise. Results During a median follow-up of 7.1 years (2 138 443 person years), 2077 incident strokes (1541 ischaemic stroke, 287 intracerebral haemorrhage, and 249 subarachnoid haemorrhage) were ascertained. The risk of incident stroke was 35% higher among those at high genetic risk (top third of polygenic score) compared with those at low genetic risk (bottom third): hazard ratio 1.35 (95% confidence interval 1.21 to 1.50), P=3.9×10 −8 . Unfavourable lifestyle (0 or 1 healthy lifestyle factors) was associated with a 66% increased risk of stroke compared with a favourable lifestyle (3 or 4 healthy lifestyle factors): 1.66 (1.45 to 1.89), P=1.19×10 −13 . The association with lifestyle was independent of genetic risk stratums. Conclusion In this cohort study, genetic and lifestyle factors were independently associated with incident stroke. These results emphasise the benefit of entire populations adhering to a healthy lifestyle, independent of genetic risk.
Vitamin D<sub>3</sub> Supplementation and Bone Health—Reply
Authors: Jenni Rosendahl, Saara Valkama, Sture Andersson
Journal: JAMA Pediatrics (2018)

In Reply We thank Li et al for their interest in our study.1 In their letter, they raise the question whether peripheral quantitative computed tomography (pQCT) is a suitable technique to analyze bone strength in infants.
Abstract 11570: Targeted Disruption of JCAD/KIAA1462, a Coronary Artery Disease-associated Gene Product, Inhibits Angiogenic Processes in Vitro and in Vivo
Authors: Tetsuya Hara, Tomoko Monguchi, Masaya Akashi, Noriko Iwamoto, Kenta Mori, Ryuji Toh, Yasuhiro Irino, Masakazu Shinohara, Mikio Furuse, Tatsuro Ishida, Ken-ichi Hirata
Journal: Circulation (2015)

Background: Recent genome-wide association studies newly identified the human KIAA1462 gene as a new locus for coronary artery disease. However, the function of the gene product, named JCAD (junctional protein associated with coronary artery disease), is unknown. Because JCAD is expressed at cell-cell junctions in endothelial cells, we hypothesized and tested whether JCAD regulates angiogenic processes in vitro and in vivo. Methods and Results: Cell culture experiments revealed impaired angiogenic ability (WST-1 assay, wound healing, and tube formation) by the knock down of JCAD with siRNA (p&lt;0.05 vs. control siRNA). We generated mice lacking JCAD (JCAD-/-) by gene-targeted deletion of JCAD to address in vivo angiogenic function. JCAD-/- mice did not show differences in development of retinal vasculature. Ex vivo aortic ring model demonstrated impaired neovascularization in aorta from JCAD-/- mice than control wild-type mice (p&lt;0.05). Tumor growth was assessed by monitoring tumor volume after the subcutaneous injection of melanoma cells into the mice. JCAD-/- mice exhibited 45% smaller tumor volume compared with wild-type mice (p&lt;0.001). Histological assessment of tumor exhibited less smooth muscle actin (SMA)-positive neovascularization determined by CD31 staining in tumor of JCAD-/- mice than wild-type mice, indicating that knock-down of JCAD inhibited the vascular maturation in angiogenic process. Conclusions: These in vitro and in vivo studies suggest that JCAD has a redundant functional role in physiological angiogenesis, but serves an essential role in pathological angiogenic process.
P3.01-99 Effect of Pembrolizumab on Patients Harboring Uncommon Epidermal Growth Factor Receptor Mutations
Authors: Y. Taniguchi, A. Tamiya, Y. Inagaki, N. Saijo, Y. Naoki, K. Otsuka, K. Nakao, K. Okishio, S. Atagi
Journal: Journal of Thoracic Oncology (2018)
Reversal of Improved Endothelial Function After Bariatric Surgery Is Mitigated by Exercise Training
Authors: Wagner Silva Dantas, Saulo Gil, Igor Hisashi Murai, Valéria Costa-Hong, Tiago Peçanha, Carlos Alberto Abujabra Merege-Filho, Ana Lúcia de Sá-Pinto, Roberto de Cleva, Marco Aurélio Santo, Rosa Maria Rodrigues Pereira, John P. Kirwan, Hamilton Roschel, Bruno Gualano
Journal: Journal of the American College of Cardiology (2018)
P1.03-06 Molecular Landscape of FGFR1 Point Mutations in Chinese Non-Small-Cell Lung Cancer Patients: A Retrospective Study
Authors: H. Wang, C. Xu, W. Wang, Q. Zhang, W. Zhuang, Y. Zhu, Y. Huang, Y. Chen, G. Chen, M. Fang, T. Lv, Y. Song
Journal: Journal of Thoracic Oncology (2018)
P1.13-33 Ex Vivo 2*2*2 Tumor Tissue Explant Culture for Precision Medicine in Immunotherapy and TKI progressors in Lung Cancer
Authors: S. Ghosh, M. Elkabets, K. Kundu, L. Roisman, D. Levitas, A. Porgador, N. Peled
Journal: Journal of Thoracic Oncology (2018)
Bone metabolism biomarkers (BMB) in hormone sensitive prostate cancer (HSPC): Results from SWOG S1216, a phase III trial of androgen deprivation therapy (ADT) +/- orteronel
Authors: P.N. Lara, E. Mayerson, E. Gertz, C. Tangen, A. Goldkorn, M. van Loan, M. Hussain, S. Gupta, J. Zhang, P. Twardowski, D.I. Quinn, N.J. Vogelzang, I. Thompson, N. Agarwal
Journal: Annals of Oncology (2018)